In Brief: Novoste Beta-Cath
This article was originally published in The Gray Sheet
Executive Summary
Novoste Beta-Cath: Feasibility study of the intracoronary radiation therapy device for reduction of restenosis "suggests 70% reduction in the rate of restenosis" with use of the system compared to historical controls, according to data presented at the Transcatheter Cardiovascular Therapeutics meeting in Washington, D.C. the week of Sept. 22 by researcher Spencer King, MD. The Beta Energy Restenosis Trial (BERT) included follow-up data from 35 patients and demonstrated an overall restenosis rate of 11%. The firm's Phase II trial commenced in July ("The Gray Sheet" Aug. 18, In Brief)...